Brad Wasserman

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer

Jamaal Rehman, Gang Han, Daniel Carvajal‐Hausdorf et al. · Modern Pathology · 2016 · 166 citations · Full text

Medicine, Cancer Biology, Oncology +10

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations

Maria Toki, Nikita Mani, James W. Smithy et al. · Journal of Thoracic Oncology · 2018 · 113 citations · Full text

Life Sciences, Immunology, Oncology +16

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance

Vasiliki Pelekanou, Daniel Carvajal‐Hausdorf, Mehmet Altan et al. · Breast Cancer Research · 2017 · 110 citations · Full text

Medicine, Immunology, Oncology +17

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial

Vasiliki Pelekanou, William E. Barlow, Zeina Nahleh et al. · Molecular Cancer Therapeutics · 2018 · 94 citations · Full text

Life Sciences, Immunology, Oncology +17

Feasibility of postmortem device acquisition for potential reuse in underserved nations

Timir S. Baman, Thomas Crawford, Patricia Sovitch et al. · Heart Rhythm · 2011 · 37 citations

Medicine, Biomedical Engineering, Preservation Technology +13